BIOTIE THERAPIES CORP. STOCK EXCHANGE ANNOUNCEMENT 15 March 2010 at 1.10 p.m. Biotie's Stock Exchange Releases published in 2009 The following list includes all Biotie Therapies Corp.'s Stock Exchange Releases and Stock Exchange Announcements published in 2009. Stock Exchange Releases, Stock Exchange Announcements and Press Releases published by Biotie are available on the company's web site at http://www.biotie.com/In_English/Investors/Stock_Exchange_Releases February 03.02.2009 Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act 17.02.2009 Clinical study started with VAP-1 antibody in rheumatoid arthritis patients March 12.03.2009 Nalmefene North-American rights acquired by Lundbeck 27.03.2009 Clinical study started with Biotie's proprietary VAP-1 antibody in psoriasis patients 27.03.2009 Biotie Therapies Corp. Financial Statement Release January 1 - December 31, 2008 27.03.2009 Biotie's Annual Financial Report 2008 published April 27.04.2009 Invitation to the Annual General Meeting of Biotie Therapies Corp. 27.04.2009 The Board of Directors of Biotie Therapies Corp. decided on the issuance of option rights 27.04.2009 Biotie Therapies Corp. Annual Report 2008 published May 15.05.2009 Biotie Therapies Corp. interim report January 1 - March 31, 2009 29.05.2009 Resolutions of the Annual General Meeting of Biotie Therapies Corp. July 23.07.2009 Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act August 07.08.2009 Biotie Therapies Corp. interim report January 1 - June 30, 2009 28.08.2009 Biotie reaches milestone in Wyeth collaboration September 14.09.2009 Biotie starts clinical study with phosphodiesterase 4 inhibitor ELB353 22.09.2009 Biotie signs an LP market making agreement with Nordea 28.09.2009 Invitation to the Extraordinary General Meeting of Biotie Therapies Corp. 28.09.2009 Peter Fellner nominated to be elected to Biotie's Board of Directors October 23.10.2009 Biotie secures committed standby equity up to 20 million Euro 23.10.2009 Biotie Therapies Corp. interim report January 1 - September 30, 2009 29.10.2009 Resolutions of the Extraordinary General Meeting of Biotie Therapies Corp. December 04.12.2009 Directed issue of new shares in Biotie Therapies Corp. to institutional investors 07.12.2009 Biotie raises EUR 7.2 million - directed issue of new shares in Biotie Therapies Corp. more than two times oversubscribed 08.12.2009 Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act 10.12.2009 Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act 14.12.2009 New Biotie shares and increase of share capital registered with the trade register 18.12.2009 Biotie´s financial information in 2010 18.12.2009 Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act relating to decrease in holdings Turku, March 15, 2010 Biotie Therapies Corp. Timo Veromaa President and CEO For further information, please contact: Virve Nurmi, Investor Relations Manager tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com <mailto:virve.nurmi@biotie.com> Distribution: NASDAQ OMX Helsinki Ltd Main Media Biotie Therapies Corp. Biotie is a drug discovery and development company focused on central nervous system and inflammatory diseases. It has a broad range of innovative small molecule and biological drug candidates at different stages of clinical and pre-clinical development. Biotie's products address diseases with high unmet medical need and significant market potential, including addiction and psychotic disorders, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary disease (COPD). The most advanced product, nalmefene for alcohol dependence, is currently in phase III clinical development by licensing partner H. Lundbeck A/S. The commercial value of the pipeline has been demonstrated through existing alliances with top-tier global pharmaceutical companies such as Lundbeck, Roche and Pfizer. Biotie has operations in Turku, Finland and Radebeul, Germany. Biotie shares are listed on NASDAQ OMX Helsinki Ltd. For more information, please refer to www.biotie.com [HUG#1393888]